首页> 外文OA文献 >The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

【2h】

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

机译：jak抑制剂在活性类风湿性关节炎患者中的安全性和有效性：三种剂量水平的双盲，安慰剂对照阶段IIa试验的结果，CP-690,550与安慰剂

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Joel M. Kremer; Bradley J. Bloom; Ferdinand C. Breedveld; John H. Coombs; Mark P. Fletcher; David Gruben; Sriram Krishnaswami; Rubén Burgos-Vargas; Bethanie Wilkinson; Cristiano A. F. Zerbini; Samuel H. Zwillich;
展开▼
作者单位

展开▼
年度 2012
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. [J] . Coombs JH, Bloom BJ, Breedveld F Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2010,第2期

机译：使用口服活性Janus激酶（JAK）抑制剂CP-690,550治疗的类风湿关节炎患者的疼痛，身体功能和健康状况得到改善：这是一项随机，双盲，安慰剂对照试验的结果。
2. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. [J] . Coombs JH, Bloom BJ, Breedveld F Annals of the Rheumatic Diseases: A Journal of Clinical Rheumatology and Connective Tissue Research . 2010,第2期

机译：使用口服活性Janus激酶（JAK）抑制剂CP-690,550治疗的类风湿关节炎患者的疼痛，身体功能和健康状况得到改善：这是一项随机，双盲，安慰剂对照试验的结果。
3. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs [J] . FleischmannR., CutoloM., GenoveseM.C., Arthritis and Rheumatism . 2012,第3期

机译：口服JAK抑制剂托法替尼（CP-690,550）或阿达木单抗单药治疗与安慰剂治疗活动性类风湿关节炎对缓解疾病的抗风湿药反应不足的患者的IIb期剂量范围研究
4. A DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED CLINICAL TRIAL TO INVESTIGATE THE EFFICACY OF TIAMULIN IN THE CONTROL OF PORCINE PROLIFERATIVE ENTEROPATHY (PPE) AND PORCINE COLONIC SPIROCHAETOSIS (PCS) UNDER FIELD CONDITIONS [C] . J. Haugegaard, K. Moller, T.K. Jensen, Congress of the International Pig Veterinary Society . 2000

机译：一种双盲随机安慰剂对照临床试验，探讨硫霉素在野生植物中猪增殖肠病（PPE）和猪结肠螺旋肌肤症（PCS）的疗效
5. A randomized, double-blind, placebo-controlled phase II trial to examine the effect of polyphenon E on endogenous hormone levels [D] . Ling, Chen 2009

机译：一项随机，双盲，安慰剂对照的II期临床试验，用于研究多肽E对内源激素水平的影响
6. The efficacy and safety of the herbal medicine geonchildan for patients with active rheumatoid arthritis: study protocol for a randomized double-blind placebo-controlled parallel pilot trial [O] . Seunghoon Lee, Yeeun Cho, Jihye Kim, 2018

机译：药物性类风湿关节炎对活动性类风湿关节炎患者的疗效和安全性：一项随机双盲安慰剂对照平行试验的研究方案
7. Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: Results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial [O] . Tak, P. P., Mease, P. J., Genovese, M. C., 2012

机译：ocrelizumab在类风湿性关节炎且对至少一种肿瘤坏死因子抑制剂反应不足的患者中的安全性和有效性：一项为期48周的随机，双盲，安慰剂对照，平行组III期试验的结果

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

著录项

引文网络

相似文献

相关主题

期刊订阅